Abliva AB (publ) (STO:ABLI)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.443
+0.001 (0.11%)
Mar 13, 2025, 12:57 PM CET
186.18%
Market Cap 713.26M
Revenue (ttm) n/a
Net Income (ttm) -89.95M
Shares Out 1.61B
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,365
Average Volume 2,851,870
Open 0.443
Previous Close 0.443
Day's Range 0.443 - 0.445
52-Week Range 0.114 - 0.455
Beta 0.75
RSI 52.92
Earnings Date Feb 21, 2025

About Abliva AB

Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yung... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ABLI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.